A growing body of evidence has demonstrated that sorafenib induces apoptosis in melanoma cells by activating pro-apoptotic proteins (Bad, Bak and Bax), down-regulating anti-apoptotic proteins (Bcl2, Bcl-Xl and Mcl-1) and inducing PARP cleavage [46, 47]. This evidence concerns the gene BCL2 and melanoma.